Observational and preclinical data suggest that GLP-1 receptor activation may reduce neuroinflammation and slow the accumulation of amyloid and tau pathology associated with Alzheimer's disease, and semaglutide is currently in Phase 3 trials for both Alzheimer's disease and Parkinson's disease [12]
Schleifer, MD, President & CEO
Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al
Liver Health and MASLD Treatment Retatrutide demonstrates remarkable efficacy in reducing liver fat and treating metabolic dysfunction-associated steatotic liver disease (MASLD)
Through direct suppression of T helper cell-mediated hyperinflammation and PKA-dependent modulation of local immune responses, GLP-1RAs help protect normal tissues (107)
Round numbers reduce reading errors at the syringe